scPharmaceuticals Stock
€4.00
Your prediction
scPharmaceuticals Stock
Pros and Cons of scPharmaceuticals in the next few years
Pros
Cons
Performance of scPharmaceuticals vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| scPharmaceuticals | -4.310% | -9.910% | -25.234% | -56.989% | -30.435% | -25.926% | - |
| Orasure Tech | - | -8.785% | -20.000% | -20.650% | -34.497% | -41.515% | -41.543% |
| SI-BONE Inc | -0.700% | -4.082% | -2.759% | 20.513% | -25.789% | -49.281% | - |
| Kewaun.scientific Dl2,50 | 1.280% | 1.935% | 12.057% | 137.594% | 30.579% | 224.103% | 69.383% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Sensibility waits at the door upon analyzing the financials of scPharmaceuticals, a company listed under the symbol SCPH, and operating within the Healthcare Equipment & Supplies industry. It's evident that there are a series of complexities and intriguing factors to consider about this company’s financial health and approach to its operations.
One of the bright spots for scPharmaceuticals is its healthy liquidity position. The company’s sizable cash reserves, as evident from the balance sheets for the years 2020 to 2022, indicate a strong liquidity position. Such reserves provide the firm with financial cushioning required to finance operations, mitigate potential risks, and capitalize on emergent opportunities without the need to rely heavily upon external financing.
Moreover, the firm's working capital over the same period has shown an upward trend. Effective working capital management could suggest a well-balanced approach to handling the firm's short-term debts and operative expenses against available short-term assets.
Comments
